Nivalis Therapeutics,Inc. (NASDAQ:NVLS) Files An 8-K Other Events

ME Staff 8-k
-
0

Nivalis Therapeutics,Inc. (NASDAQ:NVLS) Files An 8-K Other Events
Item 8.01 Other Events

On November 28, 2016, Nivalis Therapeutics, Inc. (the “Company”) issued a press release announcing results from the Company’s Phase 2 trial of Cavosonstat for treatment of Cystic Fibrosis. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. The Company also held a conference call on November 28, 2016 discussing these trial results, and a copy of the slides presented on the call are attached as Exhibit 99.2 and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number and Description

99.1 Press Release, dated November 28, 2016.

99.2 Slide deck, dated November 28, 2016


About Nivalis Therapeutics, Inc. (NASDAQ:NVLS)

Nivalis Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. It operates through discovering and development of potential drugs segment. Its operations are focused on discovery and development of its portfolio of GSNOR inhibitors, including N91115. Its product candidate, N91115, is a small molecule compound that addresses a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) resulting from mutations in the CFTR gene, the underlying cause of CF. The Company is conducting a Phase II clinical trial designed to demonstrate the safety of a triple therapy of N91115 along with lumacaftor/ivacaftor in over 130 adult CF patients homozygous for F508del.

Nivalis Therapeutics, Inc. (NASDAQ:NVLS) Recent Trading Information

Nivalis Therapeutics, Inc. (NASDAQ:NVLS) closed its last trading session down -0.03 at 6.25 with 9,943 shares trading hands.